COMPASS Pathways plc

NasdaqGS CMPS

COMPASS Pathways plc Interest Coverage Ratio for the year ending December 31, 2023: -56.06

COMPASS Pathways plc Interest Coverage Ratio is -56.06 for the year ending December 31, 2023. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqGS: CMPS

COMPASS Pathways plc

CEO	Mr. Kabir Kumar Nath M.A., M.B.A.
IPO Date	Sept. 18, 2020
Location	United Kingdom
Headquarters	33 Broadwick Street
Employees	186
Sector	Healthcare
Industries Mental Health Biotechnology Clinical Trials Drugstores & Retail Pharmacies Pharmaceuticals

Description

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years